Raj P D.

Senior Vice President, Global Regulatory Affairs, Innovent Biologics.

Role: Senior Vice President, Global Regulatory Affairs at Innovent Biologics
Location: Chicago, IL, US
LinkedIn followers: 500 followers

General Business & ManagementView LinkedIn profile

About Raj P D.

Pharmaceutical drug developer and an adaptive regulatory affairs professional…

Experience

Senior Vice President, Global Regulatory Affairs
Innovent Biologics
Mar 2024 — Present · US

Education

Dr. ALM Institute of Medical Sciences
MS, Medical Biochemistry
1992 — 1994
San Diego State University
Masters Degree (Certified), Regulatory Affairs
2009 — 2011
University of Wisconsin-Madison
Post-Doctorate, Molecular Biochemistry
2000 — 2001
University of Wisconsin-Madison and University of Madras, India
Integrated PhD, Biotechnology Interdisciplinary Biochemistry
1995 — 2000

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@innoventbio.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Innovent Biologics

Pharmaceutical Manufacturing · 868 employees · Founded 2011

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically. Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies.

innoventbio.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Raj P D.

Experience

Senior Vice President, Global Regulatory Affairs

Education

Dr. ALM Institute of Medical Sciences

San Diego State University

University of Wisconsin-Madison

University of Wisconsin-Madison and University of Madras, India

Find verified contacts for anyone on LinkedIn